MiMedx Group, Inc. entered into a definitive Agreement and Plan of Merger with Sanara MedTech Inc., under which MiMedx will acquire Sanara in an all-stock and cash transaction valued at $33.00 per share in cash plus 0.4735 shares of MiMedx common stock for each Sanara share. The deal is supported by a $300 million debt commitment from Hayfin Capital Management LLP to fund the acquisition, contingent upon customary closing conditions including shareholder approval and antitrust clearance. Termination fees are set at approximately $9.66 million payable by Sanara and $22.54 million payable by MiMedx under specific circumstances. MiMedx Group, Inc. operates in the medical technology industry, specializing in the collection, processing, and distribution of allogeneic amniotic membrane products for regenerative medicine.

MiMedx Group, Inc. reported a second quarter 2026 net loss of $15 million on net sales of $64 million, a 35% year-over-year decline driven by a 61% drop in Wound segment revenue due to Medicare reimbursement changes. Surgical sales grew 15% to $39 million. The company announced a definitive agreement to acquire Sanara MedTech Inc. for approximately $350 million in enterprise value, paying $33 per share in cash and 0.4735 shares of MiMedx stock per Sanara share. The transaction is financed by a new $300 million term loan from Hayfin Capital Management and existing cash, with expected closing by year-end 2026 subject to regulatory approvals and shareholder consent. MiMedx reiterated its full-year 2026 net sales guidance of $260-290 million. The company operates in the healthcare sector, providing placental-derived healing solutions for wound care and surgical applications.

MiMedx Group, Inc. entered into a definitive merger agreement to acquire Sanara MedTech Inc. for approximately $350 million in enterprise value. The transaction values each share of Sanara common stock at $35.00, consisting of $33.00 per share in cash and 0.4735 shares of MiMedx common stock valued at $2.00 per share based on the five-day average closing price prior to July 29, 2026. MiMedx will finance the cash portion using existing cash and a new $300 million senior secured term loan facility from Hayfin Capital Management, LLP, which will replace its existing credit agreement. The boards of both companies unanimously approved the deal, which is expected to close by year-end 2026 subject to Sanara shareholder approval and regulatory clearances. MiMedx operates in the regenerative medicine sector, providing biological products for wound care, burn treatment, and surgical applications.